Response Genetics, Inc
Response Genetics, Inc (RGDXQ) Stock Competitors & Peer Comparison
See (RGDXQ) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RGDXQ | $0.00 | +0.00% | 3.9K | N/A | -$0.39 | N/A |
| WUXAY | $15.94 | -1.06% | 45.9B | 15.63 | $1.02 | +1.76% |
| LZAGF | $649.18 | +3.79% | 45.5B | 39.45 | $16.51 | +0.49% |
| WUXIF | $15.00 | +8.07% | 44.8B | 14.85 | $1.01 | +3.26% |
| LZAGY | $63.10 | +0.41% | 44.7B | 38.05 | $1.65 | +0.91% |
| ERFSF | $74.47 | +0.38% | 12.4B | 23.87 | $2.97 | +1.19% |
| BMXMF | $84.00 | +2.84% | 9.9B | 21.65 | $3.88 | +1.22% |
| BMXXY | $7.91 | -4.70% | 9.3B | 20.28 | $0.39 | +1.31% |
| SKHCF | $14.58 | +21.50% | 7.2B | 18.46 | $0.79 | +4.98% |
| SKHHY | $13.42 | +0.75% | 6.7B | 17.25 | $0.79 | +5.38% |
Stock Comparison
RGDXQ vs WUXAY Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, WUXAY has a market cap of 45.9B. Regarding current trading prices, RGDXQ is priced at $0.00, while WUXAY trades at $15.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas WUXAY's P/E ratio is 15.63. In terms of profitability, RGDXQ's ROE is -1.27%, compared to WUXAY's ROE of +0.27%. Regarding short-term risk, RGDXQ is more volatile compared to WUXAY. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check WUXAY's competition here
RGDXQ vs LZAGF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, LZAGF has a market cap of 45.5B. Regarding current trading prices, RGDXQ is priced at $0.00, while LZAGF trades at $649.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas LZAGF's P/E ratio is 39.45. In terms of profitability, RGDXQ's ROE is -1.27%, compared to LZAGF's ROE of +0.10%. Regarding short-term risk, RGDXQ is more volatile compared to LZAGF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check LZAGF's competition here
RGDXQ vs WUXIF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, WUXIF has a market cap of 44.8B. Regarding current trading prices, RGDXQ is priced at $0.00, while WUXIF trades at $15.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas WUXIF's P/E ratio is 14.85. In terms of profitability, RGDXQ's ROE is -1.27%, compared to WUXIF's ROE of +0.27%. Regarding short-term risk, RGDXQ is more volatile compared to WUXIF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check WUXIF's competition here
RGDXQ vs LZAGY Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, LZAGY has a market cap of 44.7B. Regarding current trading prices, RGDXQ is priced at $0.00, while LZAGY trades at $63.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas LZAGY's P/E ratio is 38.05. In terms of profitability, RGDXQ's ROE is -1.27%, compared to LZAGY's ROE of +0.10%. Regarding short-term risk, RGDXQ is more volatile compared to LZAGY. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check LZAGY's competition here
RGDXQ vs ERFSF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, ERFSF has a market cap of 12.4B. Regarding current trading prices, RGDXQ is priced at $0.00, while ERFSF trades at $74.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas ERFSF's P/E ratio is 23.87. In terms of profitability, RGDXQ's ROE is -1.27%, compared to ERFSF's ROE of +0.12%. Regarding short-term risk, RGDXQ is more volatile compared to ERFSF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check ERFSF's competition here
RGDXQ vs BMXMF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, BMXMF has a market cap of 9.9B. Regarding current trading prices, RGDXQ is priced at $0.00, while BMXMF trades at $84.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas BMXMF's P/E ratio is 21.65. In terms of profitability, RGDXQ's ROE is -1.27%, compared to BMXMF's ROE of +0.10%. Regarding short-term risk, RGDXQ is more volatile compared to BMXMF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check BMXMF's competition here
RGDXQ vs BMXXY Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, BMXXY has a market cap of 9.3B. Regarding current trading prices, RGDXQ is priced at $0.00, while BMXXY trades at $7.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas BMXXY's P/E ratio is 20.28. In terms of profitability, RGDXQ's ROE is -1.27%, compared to BMXXY's ROE of +0.10%. Regarding short-term risk, RGDXQ is more volatile compared to BMXXY. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check BMXXY's competition here
RGDXQ vs SKHCF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, SKHCF has a market cap of 7.2B. Regarding current trading prices, RGDXQ is priced at $0.00, while SKHCF trades at $14.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas SKHCF's P/E ratio is 18.46. In terms of profitability, RGDXQ's ROE is -1.27%, compared to SKHCF's ROE of +0.06%. Regarding short-term risk, RGDXQ is more volatile compared to SKHCF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check SKHCF's competition here
RGDXQ vs SKHHY Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, SKHHY has a market cap of 6.7B. Regarding current trading prices, RGDXQ is priced at $0.00, while SKHHY trades at $13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas SKHHY's P/E ratio is 17.25. In terms of profitability, RGDXQ's ROE is -1.27%, compared to SKHHY's ROE of +0.05%. Regarding short-term risk, RGDXQ is more volatile compared to SKHHY. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check SKHHY's competition here
RGDXQ vs HNGZY Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, HNGZY has a market cap of 6.2B. Regarding current trading prices, RGDXQ is priced at $0.00, while HNGZY trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas HNGZY's P/E ratio is 26.67. In terms of profitability, RGDXQ's ROE is -1.27%, compared to HNGZY's ROE of +0.04%. Regarding short-term risk, RGDXQ is more volatile compared to HNGZY. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check HNGZY's competition here
RGDXQ vs DSRLF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, DSRLF has a market cap of 3.9B. Regarding current trading prices, RGDXQ is priced at $0.00, while DSRLF trades at $73.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas DSRLF's P/E ratio is 24.13. In terms of profitability, RGDXQ's ROE is -1.27%, compared to DSRLF's ROE of +0.12%. Regarding short-term risk, RGDXQ is more volatile compared to DSRLF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check DSRLF's competition here
RGDXQ vs TCGGY Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, TCGGY has a market cap of 2.4B. Regarding current trading prices, RGDXQ is priced at $0.00, while TCGGY trades at $38.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas TCGGY's P/E ratio is 29.08. In terms of profitability, RGDXQ's ROE is -1.27%, compared to TCGGY's ROE of -0.09%. Regarding short-term risk, RGDXQ is more volatile compared to TCGGY. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check TCGGY's competition here
RGDXQ vs VIMGF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, VIMGF has a market cap of 2.4B. Regarding current trading prices, RGDXQ is priced at $0.00, while VIMGF trades at $4.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas VIMGF's P/E ratio is 64.29. In terms of profitability, RGDXQ's ROE is -1.27%, compared to VIMGF's ROE of +0.05%. Regarding short-term risk, RGDXQ is more volatile compared to VIMGF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check VIMGF's competition here
RGDXQ vs TCHBF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, TCHBF has a market cap of 2.2B. Regarding current trading prices, RGDXQ is priced at $0.00, while TCHBF trades at $177.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas TCHBF's P/E ratio is -15.95. In terms of profitability, RGDXQ's ROE is -1.27%, compared to TCHBF's ROE of -0.09%. Regarding short-term risk, RGDXQ is more volatile compared to TCHBF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check TCHBF's competition here
RGDXQ vs STSEY Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, STSEY has a market cap of 1.7B. Regarding current trading prices, RGDXQ is priced at $0.00, while STSEY trades at $5.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas STSEY's P/E ratio is -78.71. In terms of profitability, RGDXQ's ROE is -1.27%, compared to STSEY's ROE of -0.01%. Regarding short-term risk, RGDXQ is more volatile compared to STSEY. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check STSEY's competition here
RGDXQ vs GNTLF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, GNTLF has a market cap of 1.3B. Regarding current trading prices, RGDXQ is priced at $0.00, while GNTLF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas GNTLF's P/E ratio is -16.67. In terms of profitability, RGDXQ's ROE is -1.27%, compared to GNTLF's ROE of -1.85%. Regarding short-term risk, RGDXQ is more volatile compared to GNTLF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check GNTLF's competition here
RGDXQ vs MRCHF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, MRCHF has a market cap of 1.1B. Regarding current trading prices, RGDXQ is priced at $0.00, while MRCHF trades at $19.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas MRCHF's P/E ratio is 25.67. In terms of profitability, RGDXQ's ROE is -1.27%, compared to MRCHF's ROE of +0.05%. Regarding short-term risk, RGDXQ is more volatile compared to MRCHF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check MRCHF's competition here
RGDXQ vs IDGXF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, IDGXF has a market cap of 345.7M. Regarding current trading prices, RGDXQ is priced at $0.00, while IDGXF trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas IDGXF's P/E ratio is 11.89. In terms of profitability, RGDXQ's ROE is -1.27%, compared to IDGXF's ROE of +0.42%. Regarding short-term risk, RGDXQ is more volatile compared to IDGXF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check IDGXF's competition here
RGDXQ vs EDTXF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, EDTXF has a market cap of 299.9M. Regarding current trading prices, RGDXQ is priced at $0.00, while EDTXF trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas EDTXF's P/E ratio is -11.36. In terms of profitability, RGDXQ's ROE is -1.27%, compared to EDTXF's ROE of +0.61%. Regarding short-term risk, RGDXQ is more volatile compared to EDTXF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check EDTXF's competition here
RGDXQ vs PFGTF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, PFGTF has a market cap of 197.6M. Regarding current trading prices, RGDXQ is priced at $0.00, while PFGTF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas PFGTF's P/E ratio is -9.66. In terms of profitability, RGDXQ's ROE is -1.27%, compared to PFGTF's ROE of -1.91%. Regarding short-term risk, RGDXQ is more volatile compared to PFGTF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check PFGTF's competition here
RGDXQ vs DIUXF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, DIUXF has a market cap of 173.5M. Regarding current trading prices, RGDXQ is priced at $0.00, while DIUXF trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas DIUXF's P/E ratio is -102.50. In terms of profitability, RGDXQ's ROE is -1.27%, compared to DIUXF's ROE of -0.04%. Regarding short-term risk, RGDXQ is more volatile compared to DIUXF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check DIUXF's competition here
RGDXQ vs AMCY Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, AMCY has a market cap of 171.3M. Regarding current trading prices, RGDXQ is priced at $0.00, while AMCY trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas AMCY's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to AMCY's ROE of N/A. Regarding short-term risk, RGDXQ is more volatile compared to AMCY. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check AMCY's competition here
RGDXQ vs NNGRF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, NNGRF has a market cap of 164.3M. Regarding current trading prices, RGDXQ is priced at $0.00, while NNGRF trades at $12.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas NNGRF's P/E ratio is 60.75. In terms of profitability, RGDXQ's ROE is -1.27%, compared to NNGRF's ROE of -0.05%. Regarding short-term risk, RGDXQ is more volatile compared to NNGRF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check NNGRF's competition here
RGDXQ vs CORBF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, CORBF has a market cap of 127.2M. Regarding current trading prices, RGDXQ is priced at $0.00, while CORBF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas CORBF's P/E ratio is 2.71. In terms of profitability, RGDXQ's ROE is -1.27%, compared to CORBF's ROE of +0.11%. Regarding short-term risk, RGDXQ is more volatile compared to CORBF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check CORBF's competition here
RGDXQ vs THOXF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, THOXF has a market cap of 73.8M. Regarding current trading prices, RGDXQ is priced at $0.00, while THOXF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas THOXF's P/E ratio is -7.45. In terms of profitability, RGDXQ's ROE is -1.27%, compared to THOXF's ROE of -1.67%. Regarding short-term risk, RGDXQ is more volatile compared to THOXF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check THOXF's competition here
RGDXQ vs TIHE Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, TIHE has a market cap of 71.9M. Regarding current trading prices, RGDXQ is priced at $0.00, while TIHE trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas TIHE's P/E ratio is 0.32. In terms of profitability, RGDXQ's ROE is -1.27%, compared to TIHE's ROE of +0.01%. Regarding short-term risk, RGDXQ is more volatile compared to TIHE. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check TIHE's competition here
RGDXQ vs BIOGF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, BIOGF has a market cap of 65.4M. Regarding current trading prices, RGDXQ is priced at $0.00, while BIOGF trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas BIOGF's P/E ratio is -0.67. In terms of profitability, RGDXQ's ROE is -1.27%, compared to BIOGF's ROE of +2.04%. Regarding short-term risk, RGDXQ is more volatile compared to BIOGF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check BIOGF's competition here
RGDXQ vs LDXHF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, LDXHF has a market cap of 64.9M. Regarding current trading prices, RGDXQ is priced at $0.00, while LDXHF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas LDXHF's P/E ratio is -8.50. In terms of profitability, RGDXQ's ROE is -1.27%, compared to LDXHF's ROE of -1.21%. Regarding short-term risk, RGDXQ is more volatile compared to LDXHF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check LDXHF's competition here
RGDXQ vs PCNEF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, PCNEF has a market cap of 62M. Regarding current trading prices, RGDXQ is priced at $0.00, while PCNEF trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas PCNEF's P/E ratio is -8.44. In terms of profitability, RGDXQ's ROE is -1.27%, compared to PCNEF's ROE of -0.05%. Regarding short-term risk, RGDXQ is more volatile compared to PCNEF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check PCNEF's competition here
RGDXQ vs BMKDF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, BMKDF has a market cap of 46.2M. Regarding current trading prices, RGDXQ is priced at $0.00, while BMKDF trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas BMKDF's P/E ratio is -44.00. In terms of profitability, RGDXQ's ROE is -1.27%, compared to BMKDF's ROE of -1.53%. Regarding short-term risk, RGDXQ is more volatile compared to BMKDF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check BMKDF's competition here
RGDXQ vs BIOQ Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, BIOQ has a market cap of 31.3M. Regarding current trading prices, RGDXQ is priced at $0.00, while BIOQ trades at $35.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas BIOQ's P/E ratio is 15.84. In terms of profitability, RGDXQ's ROE is -1.27%, compared to BIOQ's ROE of -0.03%. Regarding short-term risk, RGDXQ is more volatile compared to BIOQ. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check BIOQ's competition here
RGDXQ vs ABDXF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, ABDXF has a market cap of 30.3M. Regarding current trading prices, RGDXQ is priced at $0.00, while ABDXF trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas ABDXF's P/E ratio is -16.00. In terms of profitability, RGDXQ's ROE is -1.27%, compared to ABDXF's ROE of -0.45%. Regarding short-term risk, RGDXQ is more volatile compared to ABDXF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check ABDXF's competition here
RGDXQ vs LDDD Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, LDDD has a market cap of 28M. Regarding current trading prices, RGDXQ is priced at $0.00, while LDDD trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas LDDD's P/E ratio is -93.40. In terms of profitability, RGDXQ's ROE is -1.27%, compared to LDDD's ROE of -0.36%. Regarding short-term risk, RGDXQ is more volatile compared to LDDD. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check LDDD's competition here
RGDXQ vs SNANF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, SNANF has a market cap of 27.5M. Regarding current trading prices, RGDXQ is priced at $0.00, while SNANF trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas SNANF's P/E ratio is -12.00. In terms of profitability, RGDXQ's ROE is -1.27%, compared to SNANF's ROE of -10.44%. Regarding short-term risk, RGDXQ is more volatile compared to SNANF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check SNANF's competition here
RGDXQ vs CLIFF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, CLIFF has a market cap of 23.1M. Regarding current trading prices, RGDXQ is priced at $0.00, while CLIFF trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas CLIFF's P/E ratio is -2.25. In terms of profitability, RGDXQ's ROE is -1.27%, compared to CLIFF's ROE of -0.11%. Regarding short-term risk, RGDXQ is more volatile compared to CLIFF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check CLIFF's competition here
RGDXQ vs ANPCY Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, ANPCY has a market cap of 22M. Regarding current trading prices, RGDXQ is priced at $0.00, while ANPCY trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas ANPCY's P/E ratio is -0.10. In terms of profitability, RGDXQ's ROE is -1.27%, compared to ANPCY's ROE of -0.90%. Regarding short-term risk, RGDXQ is more volatile compared to ANPCY. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check ANPCY's competition here
RGDXQ vs PCHM Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, PCHM has a market cap of 22M. Regarding current trading prices, RGDXQ is priced at $0.00, while PCHM trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas PCHM's P/E ratio is -0.02. In terms of profitability, RGDXQ's ROE is -1.27%, compared to PCHM's ROE of +0.25%. Regarding short-term risk, RGDXQ is more volatile compared to PCHM. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check PCHM's competition here
RGDXQ vs VILGF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, VILGF has a market cap of 20.7M. Regarding current trading prices, RGDXQ is priced at $0.00, while VILGF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas VILGF's P/E ratio is -0.30. In terms of profitability, RGDXQ's ROE is -1.27%, compared to VILGF's ROE of N/A. Regarding short-term risk, RGDXQ is more volatile compared to VILGF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check VILGF's competition here
RGDXQ vs JMPHF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, JMPHF has a market cap of 15.2M. Regarding current trading prices, RGDXQ is priced at $0.00, while JMPHF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas JMPHF's P/E ratio is 8.00. In terms of profitability, RGDXQ's ROE is -1.27%, compared to JMPHF's ROE of +0.31%. Regarding short-term risk, RGDXQ is more volatile compared to JMPHF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check JMPHF's competition here
RGDXQ vs IZOZF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, IZOZF has a market cap of 13.1M. Regarding current trading prices, RGDXQ is priced at $0.00, while IZOZF trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas IZOZF's P/E ratio is -9.50. In terms of profitability, RGDXQ's ROE is -1.27%, compared to IZOZF's ROE of +0.48%. Regarding short-term risk, RGDXQ is more volatile compared to IZOZF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check IZOZF's competition here
RGDXQ vs MXDHF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, MXDHF has a market cap of 8.6M. Regarding current trading prices, RGDXQ is priced at $0.00, while MXDHF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas MXDHF's P/E ratio is -0.12. In terms of profitability, RGDXQ's ROE is -1.27%, compared to MXDHF's ROE of +4.03%. Regarding short-term risk, RGDXQ is more volatile compared to MXDHF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check MXDHF's competition here
RGDXQ vs IDXG Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, IDXG has a market cap of 8M. Regarding current trading prices, RGDXQ is priced at $0.00, while IDXG trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas IDXG's P/E ratio is 2.07. In terms of profitability, RGDXQ's ROE is -1.27%, compared to IDXG's ROE of +2.15%. Regarding short-term risk, RGDXQ is more volatile compared to IDXG. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check IDXG's competition here
RGDXQ vs ANPCF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, ANPCF has a market cap of 6.5M. Regarding current trading prices, RGDXQ is priced at $0.00, while ANPCF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas ANPCF's P/E ratio is -0.33. In terms of profitability, RGDXQ's ROE is -1.27%, compared to ANPCF's ROE of -0.90%. Regarding short-term risk, RGDXQ is more volatile compared to ANPCF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check ANPCF's competition here
RGDXQ vs IMMVF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, IMMVF has a market cap of 6.1M. Regarding current trading prices, RGDXQ is priced at $0.00, while IMMVF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas IMMVF's P/E ratio is -0.50. In terms of profitability, RGDXQ's ROE is -1.27%, compared to IMMVF's ROE of -3.53%. Regarding short-term risk, RGDXQ is more volatile compared to IMMVF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check IMMVF's competition here
RGDXQ vs SQIDF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, SQIDF has a market cap of 6.1M. Regarding current trading prices, RGDXQ is priced at $0.00, while SQIDF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas SQIDF's P/E ratio is -0.37. In terms of profitability, RGDXQ's ROE is -1.27%, compared to SQIDF's ROE of +4.47%. Regarding short-term risk, RGDXQ is more volatile compared to SQIDF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check SQIDF's competition here
RGDXQ vs PMSNF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, PMSNF has a market cap of 5.8M. Regarding current trading prices, RGDXQ is priced at $0.00, while PMSNF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas PMSNF's P/E ratio is -1.00. In terms of profitability, RGDXQ's ROE is -1.27%, compared to PMSNF's ROE of +0.34%. Regarding short-term risk, RGDXQ is more volatile compared to PMSNF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check PMSNF's competition here
RGDXQ vs AVCRF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, AVCRF has a market cap of 4.8M. Regarding current trading prices, RGDXQ is priced at $0.00, while AVCRF trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas AVCRF's P/E ratio is -4.70. In terms of profitability, RGDXQ's ROE is -1.27%, compared to AVCRF's ROE of -1.41%. Regarding short-term risk, RGDXQ is more volatile compared to AVCRF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check AVCRF's competition here
RGDXQ vs VRCDF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, VRCDF has a market cap of 4.5M. Regarding current trading prices, RGDXQ is priced at $0.00, while VRCDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas VRCDF's P/E ratio is -0.10. In terms of profitability, RGDXQ's ROE is -1.27%, compared to VRCDF's ROE of -1.93%. Regarding short-term risk, RGDXQ is less volatile compared to VRCDF. This indicates potentially lower risk in terms of short-term price fluctuations for RGDXQ.Check VRCDF's competition here
RGDXQ vs RNVA Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, RNVA has a market cap of 4.3M. Regarding current trading prices, RGDXQ is priced at $0.00, while RNVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas RNVA's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to RNVA's ROE of +0.23%. Regarding short-term risk, RGDXQ is more volatile compared to RNVA. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check RNVA's competition here
RGDXQ vs TDSGF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, TDSGF has a market cap of 4M. Regarding current trading prices, RGDXQ is priced at $0.00, while TDSGF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas TDSGF's P/E ratio is -4.00. In terms of profitability, RGDXQ's ROE is -1.27%, compared to TDSGF's ROE of -9.19%. Regarding short-term risk, RGDXQ is more volatile compared to TDSGF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check TDSGF's competition here
RGDXQ vs IBXXF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, IBXXF has a market cap of 3.3M. Regarding current trading prices, RGDXQ is priced at $0.00, while IBXXF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas IBXXF's P/E ratio is -1.50. In terms of profitability, RGDXQ's ROE is -1.27%, compared to IBXXF's ROE of +1.43%. Regarding short-term risk, RGDXQ is more volatile compared to IBXXF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check IBXXF's competition here
RGDXQ vs ICBU Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, ICBU has a market cap of 3M. Regarding current trading prices, RGDXQ is priced at $0.00, while ICBU trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas ICBU's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to ICBU's ROE of -0.22%. Regarding short-term risk, RGDXQ is more volatile compared to ICBU. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check ICBU's competition here
RGDXQ vs CHHL Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, CHHL has a market cap of 1.8M. Regarding current trading prices, RGDXQ is priced at $0.00, while CHHL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas CHHL's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to CHHL's ROE of +0.00%. Regarding short-term risk, RGDXQ is less volatile compared to CHHL. This indicates potentially lower risk in terms of short-term price fluctuations for RGDXQ.Check CHHL's competition here
RGDXQ vs SLDX Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, SLDX has a market cap of 1.4M. Regarding current trading prices, RGDXQ is priced at $0.00, while SLDX trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas SLDX's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to SLDX's ROE of +0.17%. Regarding short-term risk, RGDXQ is more volatile compared to SLDX. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check SLDX's competition here
RGDXQ vs IVRO Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, IVRO has a market cap of 1.2M. Regarding current trading prices, RGDXQ is priced at $0.00, while IVRO trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas IVRO's P/E ratio is -0.56. In terms of profitability, RGDXQ's ROE is -1.27%, compared to IVRO's ROE of +0.06%. Regarding short-term risk, RGDXQ is more volatile compared to IVRO. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check IVRO's competition here
RGDXQ vs DIGP Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, DIGP has a market cap of 1.1M. Regarding current trading prices, RGDXQ is priced at $0.00, while DIGP trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas DIGP's P/E ratio is -1.04. In terms of profitability, RGDXQ's ROE is -1.27%, compared to DIGP's ROE of +0.96%. Regarding short-term risk, RGDXQ is more volatile compared to DIGP. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check DIGP's competition here
RGDXQ vs EPGNF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, EPGNF has a market cap of 982.2K. Regarding current trading prices, RGDXQ is priced at $0.00, while EPGNF trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas EPGNF's P/E ratio is -0.30. In terms of profitability, RGDXQ's ROE is -1.27%, compared to EPGNF's ROE of +0.03%. Regarding short-term risk, RGDXQ is more volatile compared to EPGNF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check EPGNF's competition here
RGDXQ vs RSHN Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, RSHN has a market cap of 857.6K. Regarding current trading prices, RGDXQ is priced at $0.00, while RSHN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas RSHN's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to RSHN's ROE of -5.42%. Regarding short-term risk, RGDXQ is more volatile compared to RSHN. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check RSHN's competition here
RGDXQ vs NSTM Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, NSTM has a market cap of 675.9K. Regarding current trading prices, RGDXQ is priced at $0.00, while NSTM trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas NSTM's P/E ratio is 0.27. In terms of profitability, RGDXQ's ROE is -1.27%, compared to NSTM's ROE of -1.25%. Regarding short-term risk, RGDXQ is more volatile compared to NSTM. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check NSTM's competition here
RGDXQ vs SZLSF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, SZLSF has a market cap of 630K. Regarding current trading prices, RGDXQ is priced at $0.00, while SZLSF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas SZLSF's P/E ratio is -0.04. In terms of profitability, RGDXQ's ROE is -1.27%, compared to SZLSF's ROE of +4.82%. Regarding short-term risk, RGDXQ is more volatile compared to SZLSF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check SZLSF's competition here
RGDXQ vs IDTA Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, IDTA has a market cap of 607.2K. Regarding current trading prices, RGDXQ is priced at $0.00, while IDTA trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas IDTA's P/E ratio is 3.75. In terms of profitability, RGDXQ's ROE is -1.27%, compared to IDTA's ROE of +0.22%. Regarding short-term risk, RGDXQ is more volatile compared to IDTA. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check IDTA's competition here
RGDXQ vs SCRSF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, SCRSF has a market cap of 600.3K. Regarding current trading prices, RGDXQ is priced at $0.00, while SCRSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas SCRSF's P/E ratio is -0.20. In terms of profitability, RGDXQ's ROE is -1.27%, compared to SCRSF's ROE of +2.02%. Regarding short-term risk, RGDXQ is more volatile compared to SCRSF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check SCRSF's competition here
RGDXQ vs MBGNF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, MBGNF has a market cap of 101.8K. Regarding current trading prices, RGDXQ is priced at $0.00, while MBGNF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas MBGNF's P/E ratio is -0.59. In terms of profitability, RGDXQ's ROE is -1.27%, compared to MBGNF's ROE of +0.26%. Regarding short-term risk, RGDXQ is more volatile compared to MBGNF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check MBGNF's competition here
RGDXQ vs NVTAQ Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, NVTAQ has a market cap of 85.9K. Regarding current trading prices, RGDXQ is priced at $0.00, while NVTAQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas NVTAQ's P/E ratio is -0.00. In terms of profitability, RGDXQ's ROE is -1.27%, compared to NVTAQ's ROE of +0.00%. Regarding short-term risk, RGDXQ is more volatile compared to NVTAQ. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check NVTAQ's competition here
RGDXQ vs HCLC Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, HCLC has a market cap of 74K. Regarding current trading prices, RGDXQ is priced at $0.00, while HCLC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas HCLC's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to HCLC's ROE of +0.11%. Regarding short-term risk, RGDXQ is more volatile compared to HCLC. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check HCLC's competition here
RGDXQ vs MEDD Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, MEDD has a market cap of 31.9K. Regarding current trading prices, RGDXQ is priced at $0.00, while MEDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas MEDD's P/E ratio is -0.01. In terms of profitability, RGDXQ's ROE is -1.27%, compared to MEDD's ROE of +0.74%. Regarding short-term risk, RGDXQ is more volatile compared to MEDD. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check MEDD's competition here
RGDXQ vs TOMDF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, TOMDF has a market cap of 14.1K. Regarding current trading prices, RGDXQ is priced at $0.00, while TOMDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas TOMDF's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to TOMDF's ROE of +0.84%. Regarding short-term risk, RGDXQ is more volatile compared to TOMDF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check TOMDF's competition here
RGDXQ vs CGNH Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, CGNH has a market cap of 12K. Regarding current trading prices, RGDXQ is priced at $0.00, while CGNH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas CGNH's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to CGNH's ROE of +1.41%. Regarding short-term risk, RGDXQ is more volatile compared to CGNH. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check CGNH's competition here
RGDXQ vs ARYC Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, ARYC has a market cap of 7.9K. Regarding current trading prices, RGDXQ is priced at $0.00, while ARYC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas ARYC's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to ARYC's ROE of +0.55%. Regarding short-term risk, RGDXQ is more volatile compared to ARYC. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check ARYC's competition here
RGDXQ vs ABMC Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, ABMC has a market cap of 4.8K. Regarding current trading prices, RGDXQ is priced at $0.00, while ABMC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas ABMC's P/E ratio is 0.01. In terms of profitability, RGDXQ's ROE is -1.27%, compared to ABMC's ROE of +0.86%. Regarding short-term risk, RGDXQ is more volatile compared to ABMC. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check ABMC's competition here
RGDXQ vs CYPS Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, CYPS has a market cap of 4.1K. Regarding current trading prices, RGDXQ is priced at $0.00, while CYPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas CYPS's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to CYPS's ROE of N/A. Regarding short-term risk, RGDXQ is more volatile compared to CYPS. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check CYPS's competition here
RGDXQ vs DMTKQ Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, DMTKQ has a market cap of 3.5K. Regarding current trading prices, RGDXQ is priced at $0.00, while DMTKQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas DMTKQ's P/E ratio is -0.00. In terms of profitability, RGDXQ's ROE is -1.27%, compared to DMTKQ's ROE of -1.06%. Regarding short-term risk, RGDXQ is more volatile compared to DMTKQ. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check DMTKQ's competition here
RGDXQ vs MEDVF Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, MEDVF has a market cap of 2.7K. Regarding current trading prices, RGDXQ is priced at $0.00, while MEDVF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas MEDVF's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to MEDVF's ROE of +2.13%. Regarding short-term risk, RGDXQ is more volatile compared to MEDVF. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check MEDVF's competition here
RGDXQ vs IHTI Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, IHTI has a market cap of 1.6K. Regarding current trading prices, RGDXQ is priced at $0.00, while IHTI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas IHTI's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to IHTI's ROE of +0.00%. Regarding short-term risk, RGDXQ is less volatile compared to IHTI. This indicates potentially lower risk in terms of short-term price fluctuations for RGDXQ.Check IHTI's competition here
RGDXQ vs GWHP Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, GWHP has a market cap of 1.3K. Regarding current trading prices, RGDXQ is priced at $0.00, while GWHP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas GWHP's P/E ratio is -0.00. In terms of profitability, RGDXQ's ROE is -1.27%, compared to GWHP's ROE of +6.19%. Regarding short-term risk, RGDXQ is more volatile compared to GWHP. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check GWHP's competition here
RGDXQ vs ROSGQ Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, ROSGQ has a market cap of 593. Regarding current trading prices, RGDXQ is priced at $0.00, while ROSGQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas ROSGQ's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to ROSGQ's ROE of -1.35%. Regarding short-term risk, RGDXQ is more volatile compared to ROSGQ. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check ROSGQ's competition here
RGDXQ vs BIOCQ Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, BIOCQ has a market cap of 263. Regarding current trading prices, RGDXQ is priced at $0.00, while BIOCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas BIOCQ's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to BIOCQ's ROE of -1.38%. Regarding short-term risk, RGDXQ is more volatile compared to BIOCQ. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check BIOCQ's competition here
RGDXQ vs HTGMQ Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, HTGMQ has a market cap of 221. Regarding current trading prices, RGDXQ is priced at $0.00, while HTGMQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas HTGMQ's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to HTGMQ's ROE of -2.73%. Regarding short-term risk, RGDXQ is more volatile compared to HTGMQ. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check HTGMQ's competition here
RGDXQ vs OPGX Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, OPGX has a market cap of 17. Regarding current trading prices, RGDXQ is priced at $0.00, while OPGX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas OPGX's P/E ratio is -0.00. In terms of profitability, RGDXQ's ROE is -1.27%, compared to OPGX's ROE of +0.46%. Regarding short-term risk, RGDXQ is more volatile compared to OPGX. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check OPGX's competition here
RGDXQ vs EPGNY Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, EPGNY has a market cap of 0. Regarding current trading prices, RGDXQ is priced at $0.00, while EPGNY trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas EPGNY's P/E ratio is -1.60. In terms of profitability, RGDXQ's ROE is -1.27%, compared to EPGNY's ROE of -0.19%. Regarding short-term risk, RGDXQ is more volatile compared to EPGNY. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check EPGNY's competition here
RGDXQ vs AGHC Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, AGHC has a market cap of 0. Regarding current trading prices, RGDXQ is priced at $0.00, while AGHC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas AGHC's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to AGHC's ROE of +2.90%. Regarding short-term risk, RGDXQ is more volatile compared to AGHC. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check AGHC's competition here
RGDXQ vs MRPS Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, MRPS has a market cap of 0. Regarding current trading prices, RGDXQ is priced at $0.00, while MRPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas MRPS's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to MRPS's ROE of N/A. Regarding short-term risk, RGDXQ is more volatile compared to MRPS. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check MRPS's competition here
RGDXQ vs BGNX Comparison May 2026
RGDXQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGDXQ stands at 3.9K. In comparison, BGNX has a market cap of 0. Regarding current trading prices, RGDXQ is priced at $0.00, while BGNX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGDXQ currently has a P/E ratio of N/A, whereas BGNX's P/E ratio is N/A. In terms of profitability, RGDXQ's ROE is -1.27%, compared to BGNX's ROE of N/A. Regarding short-term risk, RGDXQ is more volatile compared to BGNX. This indicates potentially higher risk in terms of short-term price fluctuations for RGDXQ.Check BGNX's competition here